Search clinical trials for: chidamide and toripalimab

Total 270709 results

Sun Yat-sen University

Recruiting

Chidamide Combined With Toripalimab in Sarcoma

Sarcoma

China
Sun Yat-sen University

Recruiting

Anti-PD-1 Antibody Combined With Histone Deacetylase Inhibitor in Patients With Advanced Cervical Cancer

Cervical Cancer | Cervix Cancer | Cervix Neoplasm

China
Peking University Cancer Hospital & Institute

Recruiting

Clinical Study of Chidamide Combined With Toripalimab in the Treatment of Advanced Melanoma

Melanoma

China
Huiqiang Huang

Unknown

Differences Between Chidamide Taken Daily and Twice a Week in Therapeutic Effect，Pharmacokinetics, Pharmacodynamics and EB Virus Activation

Lymphoma, Extranodal NK-T-Cell | EBV
Cancer Institute and Hospital, Chinese Academy...

Unknown

Chidamide for Patients With Relapse or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma

Experimental
Ruihua Xu

Recruiting

Tucidinostat Plus PD-1 Inhibitor and Bevacizumab for Advanced Esophagus Cancer, AEG, Gastric Cancer

Esophageal Squamous Cell Cancer, Adenocarcinoma of Esophagogastric Junction, Gastric Adenocarcinoma

China
Sun Yat-sen University

Recruiting

Chidamide Plus PD-1 Plus Paclitaxel of Neoadjuvant Treatment in Low HR Expression,HER2-negative Early Breast Cancer.

Breast Cancer

China
Sun Yat-sen University

Recruiting

Chidamide Combined With Zimberelimab in the Treatment of Metastatic Triple-negative Breast Cancer Patients

Triple Negative Breast Cancer

China
Sun Yat-sen University

Unknown

Chidamide for Patients With Recurrent and Metastatic Epstein-Barr Virus (EBV)-Associated Solid Tumors

Experimental Tumor

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

SHR2554 Clinical Study of Chidamide in the Treatment of T-cell Lymphoma

Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy

China
Zhejiang University

Recruiting

Low-dose Chidamide Maintenance Therapy After Allo-HSCT for T-cell Acute Lymphoblastic Leukemia or T-cell Lymphomas

T Lymphoblastic Leukemia/Lymphoma

China
Sichuan University

Recruiting

Chidamide Prevents Recurrence of High-risk AML After Allo-HSCT

Leukemia, Myeloid, Acute

China
Cancer Institute and Hospital, Chinese Academy...

Unknown

Maintenance Treatment of Chidamide in Stage IV or Relapsed/Refractory Extranodal NK/T-cell Lymphoma

Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type

China
Liling Zhang
CSPC Ouyi Pharmaceutical Co., Ltd.

Recruiting

Prospective, Single Arm, Single Center Study of Duvelisib Combined With Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma (PTCL)

Newly Diagnosed Peripheral T-cell Lymphoma

China
Peking University
Peking University International Hospital; Hebei Medical University Fourth Hospital

Unknown

Chidamide Maintenance After Autologous Hematopoietic Stem Cell Transplantation for Relapsed, Refractory or High-risk Lymphoma

Experimental Tumor

China
Dong mei

Unknown

Chidamide for Advanced Cephalic and Cervical Adenocystic Carcinoma: Evaluation of Efficiency and Safety

Adenocystic Carcinoma

China
The First Affiliated Hospital with Nanjing Medical...

Recruiting

A Retrospective Clinical Study on the First-line Maintenance Treatment of PTCL With Chidamide.

PTCL

China
Ruijin Hospital

Unknown

Chidamide Plus Chemotherapy in the Treatment of Peripheral T-cell Lymphoma

Peripheral T Cell Lymphoma

China
Coherus Biosciences, Inc.

Not yet recruiting

A Study of CHS-1000 in Participants With Advanced or Metastatic Solid Tumors

Advanced or Metastatic Solid Tumors
The First Affiliated Hospital of Zhengzhou University

Not yet recruiting

Chidamide Plus Camrelizumab as Second-line Therapy for Advanced ESCC Treated With PD-1 Blockade

Esophageal Squamous Cell Carcinoma
Peking Union Medical College Hospital
Peking University Third Hospital; Dongzhimen Hospital, Beijing; Beijing Longfu...

Recruiting

Sintilimab Plus Chidamide in the Treatment of Relapsed and Refractory Cutaneous T-cell Lymphoma: a Multicenter Phase II Study

Cutaneous T-cell Lymphoma

China
Sun Yat-sen University

Recruiting

Study of Chidamide as a Single-agent Treatment for Patients With Relapse or Refractory B-NHL

Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma (NHL)

China
Guangdong Provincial People's Hospital

Unknown

Chidamide for Refractory/Relapsed Peripheral T Cell Lymphoma

Peripheral T Cell Lymphoma

China
The First Affiliated Hospital of Soochow University

Recruiting

Study of Chidamide for Steroid-resistant/Steroid-dependent Severe cGVHD

Safety and Efficacy

China
Beijing 302 Hospital

Not yet recruiting

Exploration of Dalpiciclib + Chidamide in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor: a Phase Ⅰb Study

HR+/HER2- Advanced Breast Cancer

China
Shandong University

Unknown

A Clinical Trial of the Low Dose Chidamide in the Management of Refractory ITP

Thrombocytopenia

China
Chipscreen Biosciences, Ltd.

Recruiting

A Study of Tucidinostat Combined With Tislelizumab as First-line Treatment in Advanced NSCLC

Non Small Cell Lung Cancer

China
Tianjin Medical University Cancer Institute and...

Recruiting

Fluzoparib in Combination With Chidamide or Camrelizumab for HRD Positive HER2 Negative Advanced Breast Cancer

Advanced HER2 Negative Breast Carcinoma | HRD+Breast Cancer

China
Tianjin Medical University Cancer Institute and...

Unknown

Neoadjuvant Treatment of Early Triple-negative Breast Cancer With Chidamide and Chemotherapy

Triple-negative Breast Cancer

China
Sun Yat-sen University

Recruiting

Chidamide With Immunotherapy for Patients With Locally Advanced or Metastatic Urothelial Carcinoma

Bladder Cancer Stage IV

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Not yet recruiting

9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial Cancer

Advanced Urothelial Carcinoma

China
Henan Cancer Hospital

Unknown

Anrotenib Plus Toripalimab Versus Toripalimab in Patients With Advanced Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma
The First Affiliated Hospital of Xiamen University
The First Affiliated Hospital with Nanjing Medical University; Shanxi Province... and other collaborators

Recruiting

Chidamide Combined With Linperlisibon for the Treatment of Refractory/Relapsed Follicular Lymphoma

Follicular Lymphoma | Relapsed Non-Hodgkin Lymphoma | Refractory B-Cell Lymphoma

China
Great Novel Therapeutics Biotech & Medicals Corporation

Recruiting

Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL)

Relapsed or Refractory Peripheral T-cell Lymphoma

Taiwan
HUYABIO International, LLC.

Completed

Safety Study of HBI-8000 in Japanese Patients With Non Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma

Japan
RemeGen Co., Ltd.

Recruiting

A Study of RC118 Plus Toripalimab in Patients With Locally Advanced Unresectable or Metastatic Solid Tumors

Advanced Solid Tumor

China
Beijing 302 Hospital

Recruiting

Outcome of Tucidinostat-Based Therapy in HR+ Metastatic Breast Cancer Patients Previously Treated With CDK4/6 Inhibitor

Breast Cancer

China
The First Affiliated Hospital of Xiamen University
The First Affiliated Hospital with Nanjing Medical University; Shanxi Province... and other collaborators

Recruiting

Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma

Peripheral T Cell Lymphoma | Relapsed Peripheral T-Cell Lymphoma | Refractory T-Cell Lymphoma

China
The First Affiliated Hospital of Soochow University

Recruiting

Study of Selinexor Combined With Chidamide in Relapsed/Refractory Acute Leukemia (AML) Patients

Acute Myeloid Leukemia (Relapsed/Refractory)

China
Ascentage Pharma Group Inc.

Recruiting

APG-1252 Monotherapy or in Combination With Other Therapeutic Agent in Subjects With Relapsed or Refractory Non-Hodgkin Lymphoma

NHL, Adult

China
Chipscreen Biosciences, Ltd.

Active, not recruiting

Trial of Chidamide in Combination With Envafolimab in Patients With PD-1 Inhibitor Resistant Advanced NSCLC.

Non Small Cell Lung Cancer

China
Sun Yat-sen University
The First Affiliated Hospital of Guangzhou Medical University; Guangzhou Panyu...

Recruiting

Study of Toripalimab for Limited-Stage Small Cell Lung Cancer Following Concurrent Chemoradiotherapy

Small Cell Lung Cancer Limited Stage

China
Henan Cancer Hospital

Recruiting

Teripalimab Plus Chemotherapy in Local Advanced Esophageal Cancer

Esophageal Cancer | Squamous Cell Carcinoma | Perioperative Period

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

A Study of Toripalimab as Consolidation Therapy After Postoperative Chemoradiotherapy in HNSCC

Head and Neck Squamous Cell Carcinomas

China
Shanghai Junshi Bioscience Co., Ltd.

Not yet recruiting

Intensive Medicines Monitoring Study of Toripalimab Monoclonal Injection (Tuoyi) .

Melanoma | Breast Cancer | Lung Cance

China
Zhejiang Genfleet Therapeutics Co., Ltd.

Completed

A Study of GFH018 in Combination With Toripalimab in Patients With Advanced Solid Tumors

Advanced Solid Tumor

China, Australia
Fudan University

Unknown

Toripalimab in the Neoadjuvant Treatment of BRAF V600 Wild Type Melanoma (FU-Name-T001)

Melanoma Stage IIIB-IV

China
Qilu Hospital of Shandong University

Not yet recruiting

Toripalimab Combined With Anlotinib in Unresectable Locally Advanced or Metastatic Acral Malignant Melanoma

Locally Advanced or Metastatic Acral Malignant Melanoma

China
Sun Yat-sen University

Active, not recruiting

Toripalimab and Anlotinib Combination Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma After Failure of at Least One Line of Platinum-Based Chemotherapy (TORAL)

Nasopharyngeal Carcinoma | Recurrent or Metastatic Nasopharyngeal Carcinoma

China
Sun Yat-sen University

Recruiting

Phase Ⅱ Study of Chidamide in Combination With CHOP in Previously Untreated Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype

Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype

China

Search clinical trials for: chidamide and toripalimab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mozambique

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations